Next Phase Newsletter

A private/family investment vehicle based in CA is making seed investments via an accelerator arm, and also has a stage-agnostic fund. Seed investments are typically $25,000-100,000, and the firm is capable of making larger investments via the fund. The firm also provides a three-month accelerator program, and works with partners in the healthcare industry to strategically invest in startups. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology, and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables and health monitoring devices. Within digital health, the firm’s interests include the following areas: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, Patient Adherence, Telemedicine. The firm is interested in both consumer applications and enterprise software. The firm works with strategic partners (including major pharma companies and health systems) to identify focus areas for innovation.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A biotech early stage investment firm was founded in 2016 and headquartered in Taipei, Taiwan. The firm invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a healthcare-focused venture investment fund. The core members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A large investment group with office in USA and Europe have invested in 265 companies across 55 countries. The firm is very active in the pharmaceutical and biotech industry, with around 70% of their portfolio being within these sectors. The firm has activity in listed companies, where they have interest in being a minority shareholder, with an investment size ranging from $10M to $200M. The firm is also interested in pre- IPO companies, with an investment size ranging from $5M to $200M in the form of equity, however the firm is only interested in companies that are planning on being listed in the stock exchange in the next 12 – 24 months. The firm has been successful in listing companies in the stock exchange, having done so with 4 companies so far, so their goal is to invest in companies who have that strategy. The firm is open to global opportunities.

The firm is looking for opportunities within the therapeutics, diagnostics and medical device sectors. The firm is agnostic in terms of subsector and indication, and will invest in all three classes of medical devices. The firm is open to pre-clinical companies.

The firm is open to all types of management teams with the caveat that the company must be planning on going public in the next 2 years. The firm prefers to lead investments and does not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm based in Western Europe with an additional office in USA closed its latest fund in 2019. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €5 million-€10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture investment fund is backed by a core investment team with members all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A clinical stage biopharmaceutical company headquartered in China with additional offices throughout USA and China is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.